



STATE OF IOWA

CHESTER J. CULVER, GOVERNOR
PATTY JUDGE, LT. GOVERNOR

DEPARTMENT OF HUMAN SERVICES
EUGENE I. GESSOW, DIRECTOR

Iowa Medicaid Mental Health Advisory Group Meeting April 17, 2009

**Location: Iowa Medicaid Enterprise
100 Army Post Rd.
Des Moines, Iowa 50315**

Time: 8:00 a.m. – 9:00 a.m.

Final Agenda

1. Welcome & Introductions
 - a) Advisory Group Members and Staff
 - b) Approval of the minutes
2. Use of Multiple Second Generation Antipsychotics
3. Proposed Clinical Prior Authorization Criterion
 - a) Extended Release Products – Status Update
 - b) Modified Formulations
4. Next Meeting Date
 - a) July 10th, 2009?

www.iadur.org

For more information contact the DUR Director, Chad Bissell, Pharm.D. at info@iadur.org or (515) 725-1271



**Iowa DUR
Atypical Antipsychotics
for the Period of
9/1/2008 through 2/28/2009**

	Distinct Member Count	% of Total
Members Using Atypical Antipsychotics		
Age 18 or Over		
Members using an Atypical Antipsychotic for Two or More Consecutive Months	5,688	54.7%
Members using Two Atypical Antipsychotics for Two or More Consecutive Months	583	5.6%
Members using Three Atypical Antipsychotics for Two or More Consecutive Months	25	0.2%
Under 18		
Members using an Atypical Antipsychotic for Two or More Consecutive Months	4,714	45.3%
Members using Two Atypical Antipsychotics for Two or More Consecutive Months	195	1.9%
Members using Three Atypical Antipsychotics for Two or More Consecutive Months	5	0.0%
Members Also Using Clozapine/Fazaclo		
Age 18 or Over		
Members using Clozapine/Fazaclo and Two Atypical Antipsychotics for Two or More Consecutive Months	6	50.0%
Under 18		
Members using Clozapine/Fazaclo and Two Atypical Antipsychotics for Two or More Consecutive Months	6	50.0%
Members Using Typical Antipsychotics		
Age 18 or Over		
Members using Typical Antipsychotic for Two or More Consecutive Months	663	90.0%
Members using Two Typical Antipsychotics for Two or More Consecutive Months	18	2.4%
Under 18		
Members using Typical Antipsychotic for Two or More Consecutive Months	74	10.0%
Members using Two Typical Antipsychotics for Two or More Consecutive Months	1	0.1%
Members Using Typical and Atypical Antipsychotics		
Age 18 or Over		
Members using Two Atypicals and One Typical	51	77.3%
Members using Two Atypicals and Two Typicals	1	1.5%
Members using Three Atypicals and One Typical	5	7.6%
Members using Three Atypicals and Two Typicals	3	4.5%
Members using Three Atypicals and Three Typicals	1	1.5%
Under 18		
Members using Two Atypicals and One Typical	3	4.5%
Members using Three Atypicals and One Typical	2	3.0%
 Total Number of Distinct Utilizers of the Pharmacy Drug Program from 9/1/2008 - 2/28/2009	 231,462	

Note: There were no members using 4 or more Atypical Antipsychotics for two consecutive months.

Modified Formulations

At the November 13th P&T Committee Meeting, the members of the P&T Committee requested the DUR Commission develop clinical prior authorization criteria for the medications currently on the Recommended Drug List which will be moving to the Preferred Drug List. These medications are modified formulations of existing products. This was originally discussed at the May 2008 DUR Meeting.

Proposed PA Criteria

Payment for a non-preferred isomer, pro-drug, metabolite, and/or alternative delivery system will only be considered for cases in which there is documentation of a recent trial and therapy failure with the original parent drug product of the same chemical entity, unless evidence is provided that use of the original product would be medically contraindicated.

Drugs to be affected:

Abilify Discmelt, Invega, Pristiq, Risperdal-M Tabs, Zyprexa Zydis